MX2021011334A - Anticuerpos que tienen especificidad para btn2 y usos de los mismos. - Google Patents
Anticuerpos que tienen especificidad para btn2 y usos de los mismos.Info
- Publication number
- MX2021011334A MX2021011334A MX2021011334A MX2021011334A MX2021011334A MX 2021011334 A MX2021011334 A MX 2021011334A MX 2021011334 A MX2021011334 A MX 2021011334A MX 2021011334 A MX2021011334 A MX 2021011334A MX 2021011334 A MX2021011334 A MX 2021011334A
- Authority
- MX
- Mexico
- Prior art keywords
- specificity
- antibodies
- btn2
- btn2a
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención está relacionada con anticuerpos que tienen especificidad para BTN2A y usos de los mismos, en particular para el tratamiento de cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19305345 | 2019-03-20 | ||
EP19219691 | 2019-12-24 | ||
PCT/EP2020/057794 WO2020188086A1 (en) | 2019-03-20 | 2020-03-20 | Antibodies having specificity for btn2 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011334A true MX2021011334A (es) | 2021-12-10 |
Family
ID=69810881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011334A MX2021011334A (es) | 2019-03-20 | 2020-03-20 | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220162305A1 (es) |
EP (1) | EP3941940A1 (es) |
JP (1) | JP2022525937A (es) |
KR (1) | KR20220007041A (es) |
CN (1) | CN113811545A (es) |
AU (1) | AU2020243076A1 (es) |
BR (1) | BR112021018611A2 (es) |
CA (1) | CA3134122A1 (es) |
IL (1) | IL286486A (es) |
MX (1) | MX2021011334A (es) |
SG (1) | SG11202109932WA (es) |
WO (1) | WO2020188086A1 (es) |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
JPS63501765A (ja) | 1985-11-01 | 1988-07-21 | インタ−ナショナル、ジェネティック、エンジニアリング インコ−ポレ−テッド | 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
JP3866760B2 (ja) | 1993-02-22 | 2007-01-10 | ザ ロックフェラー ユニバーシティ | 一過性トランスフェクションによる高力価のヘルパーフリーのレトロウイルスの生産 |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
US5994524A (en) | 1994-07-13 | 1999-11-30 | Chugai Seiyaku Kabushiki Kaisha | Polynucleotides which encode reshaped IL-8-specific antibodies and methods to produce the same |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
WO1998045322A2 (en) | 1997-04-10 | 1998-10-15 | Royal Netherlands Academy Of Arts And Sciences | Diagnosis method and reagents |
WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
WO2006033386A1 (ja) | 2004-09-22 | 2006-03-30 | Kirin Beer Kabushiki Kaisha | 安定化されたヒトIgG4抗体 |
WO2006116192A2 (en) * | 2005-04-21 | 2006-11-02 | Medarex, Inc. | Irta-1 antibodies and their uses |
CA2681974C (en) | 2007-03-29 | 2019-12-31 | Genmab A/S | Bispecific antibodies and methods for production thereof |
JP6071165B2 (ja) | 2007-05-31 | 2017-02-01 | ゲンマブ エー/エス | 安定なIgG4抗体 |
GB0717101D0 (en) * | 2007-09-03 | 2007-10-10 | Cambridge Entpr Ltd | Tumour marker |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
WO2012080769A1 (en) | 2010-12-15 | 2012-06-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd277 antibodies and uses thereof |
AU2014354587A1 (en) * | 2013-11-29 | 2016-06-02 | Csl Limited | Method of treating cancer |
EP3319993B1 (en) * | 2015-07-10 | 2020-01-15 | Genmab A/S | Axl-specific antibody-drug conjugates for cancer treatment |
BR112018067525A2 (pt) * | 2016-02-26 | 2019-02-05 | Centre Nat Rech Scient | anticorpos tendo especificidade para o btla e seus usos |
EP3684795A1 (en) | 2017-09-21 | 2020-07-29 | Imcheck Therapeutics SAS | Antibodies having specificity for btn2 and uses thereof |
-
2020
- 2020-03-20 JP JP2021556522A patent/JP2022525937A/ja active Pending
- 2020-03-20 SG SG11202109932W patent/SG11202109932WA/en unknown
- 2020-03-20 KR KR1020217033985A patent/KR20220007041A/ko unknown
- 2020-03-20 CN CN202080031271.7A patent/CN113811545A/zh active Pending
- 2020-03-20 MX MX2021011334A patent/MX2021011334A/es unknown
- 2020-03-20 BR BR112021018611A patent/BR112021018611A2/pt unknown
- 2020-03-20 CA CA3134122A patent/CA3134122A1/en active Pending
- 2020-03-20 EP EP20711210.3A patent/EP3941940A1/en active Pending
- 2020-03-20 US US17/440,836 patent/US20220162305A1/en active Pending
- 2020-03-20 AU AU2020243076A patent/AU2020243076A1/en active Pending
- 2020-03-20 WO PCT/EP2020/057794 patent/WO2020188086A1/en unknown
-
2021
- 2021-09-19 IL IL286486A patent/IL286486A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20220162305A1 (en) | 2022-05-26 |
IL286486A (en) | 2021-12-01 |
EP3941940A1 (en) | 2022-01-26 |
AU2020243076A1 (en) | 2021-10-14 |
SG11202109932WA (en) | 2021-10-28 |
CA3134122A1 (en) | 2020-09-24 |
WO2020188086A1 (en) | 2020-09-24 |
CN113811545A (zh) | 2021-12-17 |
JP2022525937A (ja) | 2022-05-20 |
BR112021018611A2 (pt) | 2021-11-23 |
KR20220007041A (ko) | 2022-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3156451A1 (en) | ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
PH12020500671A1 (en) | Antibodies specific for gucy2c and uses thereof | |
PH12019502283A1 (en) | Anti-lag3 antibodies | |
MX2019012233A (es) | Anticuerpos anti-sirpa. | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
PH12020552229A1 (en) | Il-11ra antibodies | |
MX2020003219A (es) | Anticuerpos que tienen especificidad para btn2 y usos de los mismos. | |
MX2022002682A (es) | Anticuerpos anti-cd73. | |
PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
MX2020008122A (es) | Anticuerpos anti-pd-1. | |
CR20230469A (es) | Anticuerpos anti-nectina-4 y usos de los mismos | |
MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
MX2021008834A (es) | Metodos de tratamiento del cancer de mama con tucatinib. | |
MX2021006865A (es) | Anticuerpos anti-alfa-sinucleina y usos de estos. | |
WO2019100052A3 (en) | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof | |
WO2019016597A3 (en) | SYNTHETIC PROTEINS AND THEIR THERAPEUTIC USES | |
CR20220228A (es) | Anticuerpos trem2 y usos de estos | |
PH12020551331A1 (en) | Treatment and prevention of pre-eclampsia | |
MX2021015766A (es) | Nuevos antigenos y metodos contra el cancer. | |
MX2020011377A (es) | Metodos y composiciones para el tratamiento de urticaria cronica. |